Edition:
United States

Profile: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

49.19USD
17 Nov 2017
Change (% chg)

$-0.30 (-0.61%)
Prev Close
$49.49
Open
$49.28
Day's High
$49.48
Day's Low
$48.50
Volume
117,248
Avg. Vol
213,379
52-wk High
$57.40
52-wk Low
$10.31

Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

As of December 31, 2016, the Company had completed Phase II clinical studies of bempedoic acid. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Company Address

Esperion Therapeutics Inc

3891 Ranchero Dr Ste 150
ANN ARBOR   MI   48108-2837
P: +1734.8873903
F: +1302.6555049

Company Web Links